LAST in the ASC Era: What the 2026 AORN Guideline Means for Plastic Surgeons & CRNAs

The Case That Should Haunt Every Cosmetic ASC

Consider a textbook scenario — the kind documented throughout the LAST case literature. A healthy 38-year-old woman comes in for an elective abdominoplasty under local anesthesia with oral sedation. She's ASA I, no cardiac history, no drug allergies. The surgeon — talented, board-certified — infiltrates a generous tumescent field. Forty minutes in, she starts complaining of a metallic taste in her mouth. She's a little more anxious than expected. The staff reassures her. Then her lips go numb. Then she seizes.

That's local anesthetic systemic toxicity — LAST — and in an office-based suite or ambulatory surgery center without a crash cart stocked with 20% lipid emulsion, that scenario can end in cardiovascular collapse and a lawsuit that eclipses every dollar of revenue the practice generated that month. A private-practice cosmetic case bills $12,000 to $25,000 cash-pay. No amount of revenue justifies an unmitigated LAST event. And yet, based on the data now in front of us, far too many facilities are flying blind.

The good news: we have new guidance. AORN's 2026 Guideline for Care of the Patient Receiving Local-Only Anesthesia — its first major revision since 2020 — dropped with fresh, evidence-based LAST protocols built precisely for the local-only and opioid-sparing era we're operating in. The bad news: the out-of-hospital preparedness gap is already wider than most of us want to admit.

Why LAST Is an ASC Problem Right Now

Here's what the data actually says — and these numbers deserve precision. A 2025 editorial in the British Journal of Anaesthesia flagged a statistic that should stop every ASC administrator cold: 23% of LAST events now occur in out-of-hospital settings, and intravenous lipid emulsion — the definitive treatment — was administered in only 12% of those cases. Read that again. Roughly one in four LAST events happens outside the hospital, and the correct antidote is being deployed less than one in eight times. That is not a rounding error. That is a system failure.

The same analysis surfaced two more data points that should make every plastic surgeon pause. A survey of board-certified plastic surgeons found that 10% reported exceeding the maximum recommended doses of local anesthetic — an uncomfortable acknowledgment in a field where tumescent infiltration volumes can climb quickly. And adverse cardiovascular reactions have been documented in up to 8% of cosmetic procedures involving local anesthetics. Eight percent. That's not rare. That's a meaningful chunk of your caseload carrying meaningful cardiac risk.

Meanwhile, the procedural landscape is shifting fast. Local-only and opioid-sparing techniques are expanding across ASCs as payers and patients both push for faster recovery and reduced narcotic exposure. StatPearls' updated 2025 review of local anesthetic toxicity specifically notes that local anesthetics now play a central role in multimodal opioid-sparing analgesia — which means cumulative exposure volumes across ASC settings are climbing. More blocks. More tumescent infiltration. More liposomal bupivacaine. More lidocaine. More risk.

The Epidemiology: Rare Until It Isn't

LAST is often dismissed as a theoretical risk because the headline incidence looks reassuring. StatPearls 2025 reports a general incidence of 2 to 2.8 per 10,000 nerve block cases. That sounds manageable until you stratify by procedure type. A comprehensive 2025 review in the Formosan Journal of Surgery estimates the rate climbs to 1 to 3 per 1,000 high-risk procedures — a tenfold increase. If your ASC runs 500 high-risk cases per year, you're looking at a statistically plausible LAST event every one to two years. Are you ready for it?

What makes LAST particularly dangerous in an ASC context is the recognition problem. The same Formosan Journal review found that nearly 50% of LAST presentations are atypical. We were trained to watch for the classic sequence: perioral numbness, tinnitus, metallic taste, progressing to seizure and cardiovascular collapse. But in a sedated patient — or a patient who's anxious and talkative — the CNS prodrome can be masked or misattributed. Patients report feeling "weird" or "dizzy." Staff assume it's anxiety or vasovagal. By the time the cardiac dysrhythmia appears, the window for early intervention has closed.

There's also a pharmacokinetic subtlety worth flagging. A 2025 review in the Canadian Journal of Anesthesia — summarized via NYSORA — found that while mean plasma concentrations of ropivacaine and bupivacaine during fascial plane blocks generally stay below toxic thresholds, a consistent minority of patients exceed accepted toxicity levels — often without overt LAST symptoms. This is the silent toxicity problem: subclinical plasma levels tipping over the edge in patients with altered protein binding, hepatic impairment, or simply pharmacokinetic outlier status, and nobody knows until something goes wrong.

What the 2026 AORN Guideline Actually Requires

Let's get into the substance of what changed. AORN's 2026 Guideline for Care of the Patient Receiving Local-Only Anesthesia is the first major revision to this document since 2020, and it was built specifically to address the evidence gaps that have emerged as local-only volumes have expanded. The guideline incorporates updated research on LAST recognition, prevention, and team response protocols — and critically, it applies to perioperative teams across all settings, including those running local-only cases where a CRNA or anesthesiologist may not be physically present at every moment.

AORN Senior Perioperative Practice Specialist Emily Jones, PhD, RN, CNOR, EBP-C, who led the guideline update, put it plainly: LAST demands a "keen eye for early signs and team preparedness for rapid response." That's not boilerplate. That's a direct call to perioperative nursing staff, scrub techs, and circulating nurses — the people most likely to be at the bedside when CNS symptoms first appear — to own their role in early recognition.

From a practical standpoint, the 2026 guideline reinforces several non-negotiable expectations for ASC and office-based OR teams:

• Pre-procedure risk stratification — identifying patients with hepatic impairment, low albumin, extremes of age, or cardiac conduction disease who carry elevated LAST risk.
• Dose calculation and documentation — calculating weight-based maximum doses before infiltration begins, not after a problem arises.
• Team-based recognition training — all perioperative personnel, not just the provider injecting, must know the early signs of LAST and understand their role in the response chain.
• Immediate availability of 20% lipid emulsion — the guideline is unambiguous: rapid-response readiness is required in local-only settings, which means Intralipid on the shelf, not on a pharmacy order.

That last point deserves emphasis. If your ASC doesn't have 20% intravenous lipid emulsion immediately accessible in every room where local anesthetics are administered, you are out of alignment with the 2026 standard of care — full stop.

Treatment: What You Do When It Happens

Treatment of LAST is time-critical, and the sequence matters. A June 2025 case report in Cureus documented a successful LAST management event following a ropivacaine cervical nerve block in an outpatient setting — and it's worth studying because it illustrates both what works and where post-stabilization monitoring practices need to evolve in ambulatory settings.

The core management algorithm, consistent with current ASRA guidelines and reinforced by the 2025 Cureus case, is:

1. Stop the local anesthetic immediately. This sounds obvious, but in a panic, surgeons sometimes continue or even increase infiltration. Stop the injection the moment LAST is suspected.
2. Airway first. Call for help. Secure the airway. High-flow oxygen. If the patient is seizing and apneic, ventilation takes priority.
3. Benzodiazepines for seizure control. Midazolam is preferred. Avoid propofol if cardiovascular instability is present — propofol is not a substitute for lipid emulsion and carries its own hemodynamic liabilities at the doses required for seizure suppression.
4. 20% intravenous lipid emulsion (Intralipid) — immediately. The lipid sink mechanism sequesters lipophilic local anesthetics — particularly bupivacaine — from the myocardium and plasma. Bolus 1.5 mL/kg over 1 minute, then infuse at 0.25 mL/kg/min. Repeat bolus if cardiovascular instability persists. The Formosan Journal of Surgery 2025 review covers five years of evolving evidence on ILE therapy optimization.
5. If cardiac arrest occurs, follow ACLS with modifications. Epinephrine doses should be reduced (<1 mcg/kg). Avoid vasopressin, calcium channel blockers, beta-blockers. Prolonged CPR may be required — lipid-bound local anesthetics can redistribute over time.

One thing the Cureus case specifically advocated: reevaluation of post-stabilization monitoring in ambulatory settings. Successfully treating LAST doesn't mean the patient is safe to go home in two hours. Recurrence of cardiovascular instability after apparent stabilization has been documented. Your discharge criteria need to account for that.

Where Pre-Op Screening Fits In — and Where VeriOp.ai Comes In

Here's the most frustrating part of the LAST picture: the majority of risk factors are identifiable in advance. Hepatic impairment that reduces local anesthetic metabolism. Low serum albumin that limits protein binding. Cardiac conduction disease that lowers the threshold for dysrhythmia. Extremes of body weight that make fixed-dose tumescent volumes dangerous. A patient on a CYP1A2 inhibitor that reduces lidocaine clearance. These aren't surprises — they're data points hiding in a patient's chart that nobody surfaced before the surgeon picked up the syringe.

This is exactly the gap that VeriOp.ai is designed to close. As an AI-driven pre-operative risk screening platform designed to meet criteria for Clinical Decision Support under the 21st Century Cures Act, VeriOp.ai surfaces the patient-specific risk signals — comorbidities, medications, lab values, procedure-specific flags — that are relevant to local anesthetic safety before the case ever gets to your OR. For plastic surgery ASCs running high local-anesthetic-volume cases, that means a surgeon knows before infiltration begins whether this patient's profile warrants dose reduction, additional monitoring, or anesthesia team involvement.

Our published validation study demonstrates how the platform performs against real clinical scenarios. This isn't about replacing clinical judgment — it's about making sure the data that should inform clinical judgment is actually in front of the provider, not buried in a chart someone scanned at 11 PM the night before surgery.

Prevention is always cheaper than treatment. A LAST event with an ICU transfer, potential litigation, and lost case revenue from a temporary facility shutdown doesn't just cost you the revenue from that one case. It costs you your reputation in a market where cosmetic patients choose surgeons largely on word-of-mouth and online reviews.

A Practical LAST Preparedness Checklist for Your ASC

Based on the 2026 AORN guideline framework and the 2025 ASRA-aligned evidence, here's what every ASC running local-only or local-plus-sedation cases needs to have locked down before January 2026 cases start:

• Intralipid 20% on the shelf, in every procedural room. Not in the pharmacy. Not down the hall. In the room. Confirm expiration dates quarterly.
• LAST response protocol posted and laminated. A cognitive aid on the wall is not weakness — it's what the evidence says saves lives in high-stress, low-frequency events.
• Weight-based dose calculation as a pre-procedure timeout item. Maximum lidocaine dose is 4.5 mg/kg plain, 7 mg/kg with epinephrine. Maximum bupivacaine is 2.5 mg/kg plain, 3 mg/kg with epi. Calculate it. Document it. Before the needle goes in.
• Annual LAST simulation for all perioperative staff. The 2026 AORN guideline calls for team-based rapid response readiness. That means your scrub tech and circulator need to know what LAST looks like — not just your CRNA.
• Pre-op screening that flags LAST risk factors. Low albumin, hepatic impairment, CYP enzyme interactions, cardiac conduction abnormalities — these should be captured and communicated before the procedure, not discovered in a post-event chart review.
• Post-stabilization monitoring protocol. If a LAST event occurs and the patient is stabilized, do not revert to standard discharge criteria. Extended monitoring and transfer protocols should be defined in advance.

The lidocaine angle flagged by the 2025 British Journal of Anaesthesia editorial deserves a final word here. Lidocaine is the workhouse of tumescent anesthesia in liposuction and body contouring. It's often treated as the "safe" local anesthetic relative to bupivacaine — but the 2025 BJ Anaesth analysis specifically called out lidocaine as an under-recognized LAST driver, particularly in high-volume tumescent cases where total milligram loads can be substantial. If your practice does significant liposuction volume, lidocaine toxicity in ambulatory surgery is a risk you need to quantify and respect.

The Bottom Line

The 2026 AORN guideline revision isn't bureaucratic paperwork. It's the field recognizing that the way we're using local anesthetics has changed — the volumes, the settings, the patient populations — and that our preparedness infrastructure hasn't kept pace. Twenty-three percent of LAST events are happening outside hospitals. Lipid emulsion is being used in 12% of those out-of-hospital cases. That gap is not an abstraction. It's a patient who seized in a cosmetic surgery suite because no one stocked Intralipid, no one calculated the dose ceiling, and no one trained the circulating nurse to recognize the metallic taste complaint as a warning shot.

For a high-volume cosmetic ASC, LAST prevention is not an academic exercise — it's a daily operational commitment. The 2026 AORN guideline gives us the framework. The evidence gives us the urgency. What we do with both is up to us.

If you're ready to close the pre-operative screening gap in your practice, VeriOp.ai was built for exactly this — surfacing the risk signals that matter before your patient is on the table, so your team can act before a complication, not in response to one.